Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163185 | 0.76 | FFAR1 (0.55) | LTA4HCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5050666 | 0.76 | LTA4H (0.69) | LTA4H | |
| SCHEMBL5569332 | 0.75 | EGFR (0.47) | HCRTR1 | |
| SCHEMBL4620158 | 0.75 | CAMKK1 (0.38) | LTA4H | |
| SCHEMBL16754893 | 0.74 | LTA4H (0.37) | LTA4HALOX5AP | |
| SCHEMBL3523231 | 0.74 | SPHK2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL15811746 | 0.74 | ABHD6 (0.54) | LTA4HCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4140738 | 0.74 | ABHD6 (0.54) | LTA4HCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3828498 | 0.73 | LTA4H (0.46) | LTA4HCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16468435 | 0.73 | LTA4H (0.49) | LTA4HCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | LTA4H 4685/4885ALOX5AP 4791/4885HCRTR1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.